[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Invited Commentary
Health Care Reform
January 25, 2010

Drug Safety: Are We Making Progress?Comment on “Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data”

Arch Intern Med. 2010;170(2):202. doi:10.1001/archinternmed.2009.496

Drug safety and efficacy are central to the missions of government agencies, industry, and clinicians. The case of the market withdrawal of rofecoxib (Vioxx; Merck & Co Inc, Whitehouse Station, New Jersey), which has been extensively discussed in the mass media, professional journals, and the courts, raises questions regarding the adequacy of governmental oversight, the integrity of the pharmaceutical industry, the role of professional journals, and the involvement of academia in pursuing this mission.

First Page Preview View Large
First page PDF preview
First page PDF preview
×